Article in Biospace.com, the most comprehensive Life Science industry news and information source
Excerpt
In the new research paper, Alzheon highlights data showing ALZ-801 demonstrates “superior selectivity” for amyloid oligomers in APOE4/4 homozygous patients with AD. The company explained in a statement that Biogen’s accelerated approval of aducanumab, an anti-amyloid therapy, confirms ALZ-801’s mechanism of action and validates “a regulatory path for a clinical study that provides strong biomarker data to support clinical outcomes.”
Alzheon’s founder, president and chief executive officer, Martin Tolar, M.D., Ph.D., said that the approval of aducanumab has allowed the industry to enter a new era of AD drug development. “The degree of amyloid oligomer selectivity appears to be the key factor that, together with pharmacokinetic properties, determines the magnitude of the benefit and risk profile for each anti-amyloid agent,” said Tolar, who was a lead author in the paper.
Read the full article here